GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (OCSE:HLUN A) » Definitions » Cyclically Adjusted Price-to-FCF

H. Lundbeck AS (OCSE:HLUN A) Cyclically Adjusted Price-to-FCF : 3.09 (As of Jul. 07, 2025)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Cyclically Adjusted Price-to-FCF?

As of today (2025-07-07), H. Lundbeck AS's current share price is kr30.30. H. Lundbeck AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was kr9.79. H. Lundbeck AS's Cyclically Adjusted Price-to-FCF for today is 3.09.

The historical rank and industry rank for H. Lundbeck AS's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

OCSE:HLUN A' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 2.22   Med: 3.3   Max: 4.17
Current: 3.09

During the past years, H. Lundbeck AS's highest Cyclically Adjusted Price-to-FCF was 4.17. The lowest was 2.22. And the median was 3.30.

OCSE:HLUN A's Cyclically Adjusted Price-to-FCF is ranked better than
97.54% of 325 companies
in the Drug Manufacturers industry
Industry Median: 32.54 vs OCSE:HLUN A: 3.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

H. Lundbeck AS's adjusted free cash flow per share data for the three months ended in Mar. 2025 was kr0.525. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is kr9.79 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


H. Lundbeck AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for H. Lundbeck AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Cyclically Adjusted Price-to-FCF Chart

H. Lundbeck AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.41 3.20 3.56

H. Lundbeck AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 3.38 3.79 3.56 2.94

Competitive Comparison of H. Lundbeck AS's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

H. Lundbeck AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

H. Lundbeck AS's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=30.30/9.79
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, H. Lundbeck AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.525/120.2000*120.2000
=0.525

Current CPI (Mar. 2025) = 120.2000.

H. Lundbeck AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -7.036 100.300 -8.432
201509 -7.589 100.200 -9.104
201512 2.721 99.800 3.277
201603 1.620 100.200 1.943
201606 1.920 100.600 2.294
201609 6.044 100.200 7.250
201612 4.587 100.300 5.497
201703 3.300 101.200 3.920
201706 2.624 101.200 3.117
201709 5.489 101.800 6.481
201712 5.175 101.300 6.141
201803 9.864 101.700 11.658
201806 6.502 102.300 7.640
201809 3.913 102.400 4.593
201812 6.271 102.100 7.383
201903 3.941 102.900 4.604
201906 -0.362 102.900 -0.423
201909 6.301 102.900 7.360
201912 1.016 102.900 1.187
202003 0.604 103.300 0.703
202006 6.720 103.200 7.827
202009 5.310 103.500 6.167
202012 4.265 103.400 4.958
202103 0.121 104.300 0.139
202106 0.455 105.000 0.521
202109 1.088 105.800 1.236
202112 0.104 106.600 0.117
202203 -0.294 109.900 -0.322
202206 0.860 113.600 0.910
202209 1.392 116.400 1.437
202212 0.756 115.900 0.784
202303 0.303 117.300 0.310
202306 1.083 116.400 1.118
202309 1.401 117.400 1.434
202312 0.808 116.700 0.832
202403 0.874 118.400 0.887
202406 1.080 118.500 1.095
202409 2.209 118.900 2.233
202412 -1.385 118.900 -1.400
202503 0.525 120.200 0.525

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


H. Lundbeck AS  (OCSE:HLUN A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


H. Lundbeck AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS Business Description

Industry
Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS Headlines

No Headlines